Finepoint Capital’s Ascendis Pharma A/S ASND Stock Holding History

Finepoint Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-179,872	Closed	-$28M	–	12
2025 Q1	$28M	Sell	179,872 -5,000	-3%	-$714K	2.14%	7
2024 Q4	$25.5M	Sell	184,872 -5,200	-3%	-$684K	1.55%	9
2024 Q3	$28.4M	Buy	190,072 +800	+0.4%	+$108K	2.06%	7
2024 Q2	$25.8M	Buy	189,272 +13,600	+8%	+$1.85M	7.33%	3
2024 Q1	$26.6M	Buy	175,672 +11,900	+7%	+$1.7M	6.81%	3
2023 Q4	$20.6M	Hold	163,772	–	–	6.51%	6
2023 Q3	$15.3M	Buy	163,772 +24,000	+17%	+$2.25M	7.64%	6
2023 Q2	$12.5M	Sell	139,772 -16,300	-10%	-$1.42M	4.32%	13
2023 Q1	$16.7M	Buy	156,072 +22,036	+16%	+$2.52M	6.39%	7
2022 Q4	$16.4M	Buy	134,036 +10,636	+9%	+$1.23M	5.29%	11
2022 Q3	$12.7M	Sell	123,400 -36,100	-23%	-$3.42M	4.19%	16
2022 Q2	$14.8M	Buy	+159,500	New	+$15M	5.13%	8

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Finepoint Capital's ASND Position: Q2 2025 in Review

Finepoint Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 179,872 shares — an estimated $28M sold.

Finepoint Capital first reported a position in ASND in Q2 2022 and held it in 12 quarters. The position peaked at $28.4M in Q3 2024. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

Finepoint Capital reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
Finepoint Capital sold 179,872 Ascendis Pharma A/S shares in Q2 2025, an estimated $28M.
Finepoint Capital first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 12 quarters.
Finepoint Capital's Ascendis Pharma A/S position peaked at $28.4M in Q3 2024.
247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.